Gilead Sciences, Inc. (GILD) stock analysis

In our weekly check, Gilead Sciences, Inc. is graded C (A to F). Of 23 checks on debt, profit, cash flow and trend: 15 pass, warnings: 2, red flags: 6.

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a Healthcare company (Drug Manufacturers - General) based in the United States, listed on NASDAQ as GILD.

What our checks show for GILD

Red flags

Warning signs

Strengths

Next earnings report: 2027-02-09

Similar companies

NVO · AMGN · PFE · AZN · NVS · BMY

Questions

What grade does Gilead Sciences, Inc. (GILD) have?

In our weekly check, Gilead Sciences, Inc. is graded C (A to F). Of 23 checks on debt, profit, cash flow and trend: 15 pass, warnings: 2, red flags: 6. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of GILD stock?

This week's biggest flags for Gilead Sciences, Inc.: High debt, Margins falling, Weak EPS growth. In total 8 of 23 checks show a warning or a red flag.

What does Gilead Sciences, Inc. do?

Gilead Sciences, Inc. is a Healthcare company (Drug Manufacturers - General) based in the United States, listed on NASDAQ as GILD.

When does Gilead Sciences, Inc. report earnings next?

The next earnings report is expected on 2027-02-09. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis